Compare Amphastar Pharmaceuticals Inc (AMPH) vs Campbell Soup Co. (CPB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Campbell Soup Co. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Campbell Soup Co. trades at $22.15 (market cap $6.58B). The key difference: Campbell Soup Co. is far larger — about 8× Amphastar Pharmaceuticals Inc's market cap, and Campbell Soup Co. pays a 7.07% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CPB | |
|---|---|---|
Market Cap | $826.08M | $6.58B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $34.03 |
52-Week Low | $16.87 | $20.00 |
Enterprise Value | $1.22B | $13.19B |
Dividend Yield | — | 7.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Campbell's (CPB) trades at $22.07, up 2.79% today, with a bearish technical signal and mixed earnings history. The stock shows attractive valuation metrics with a P/E of 10.82 and P/S of 0.67, but profitability remains modest with a 6.12% net margin. Recent news highlights cost-cutting efforts and a 7% dividend yield, though sales declines and margin pressures persist.
Outlook is cautious due to weak analyst consensus (only 3.45% buy ratings) and structural margin challenges. The stock offers value and income potential but faces headwinds from inflation and competitive pressures. Risks include execution on cost savings and consumer demand volatility, with the consensus price target at $20.00 suggesting limited upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →
